X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

By Jay Taylor  |    April 25, 2017
Bringing a single new medicine to market requires substantial resources over many years. To ensure continued investment in the development of tomorrow’s breakthrough treatments and cures,...   Read More

Trading fair means upholding the law: A focus on patents

By Jay Taylor  |    April 18, 2017
Patents are the linchpin of innovation. In the United States and other countries around the world, they provide temporary protection for new inventions. A fair, stable and predictable patent...   Read More

Enforcing unmet trade obligations protects U.S. innovation

By Jay Taylor  |    April 11, 2017
The United States leads the world in medical innovation, helping patients across the globe access the latest life-saving treatments and cures. Trade agreements with other nations serve as the...   Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

By Michelle Drozd  |    March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy...   Read More

How do multiple sclerosis patients define value?

By Lauren Neves  |    February 24, 2017
There are crucial conversations occurring in the health care system about how value is defined. To explore how multiple sclerosis (MS) patients, providers and payers view value, Real Endpoints...   Read More

The Value Collaborative: Advancing private market solutions to achieve better health, lower costs

By Stephen J. Ubl  |    January 31, 2017
Each day, biopharmaceutical researchers push the bounds of medical science to find new treatments and cures to the most complex conditions facing patients. The launch of GOBOLDLY™, our new...   Read More

ICER glosses over significant progress in MS treatment

By Holly Campbell  |    November 30, 2016
Multiple sclerosis (MS) is a devastating chronic autoimmune disease that can affect a person’s brain, spinal cord and optic nerves, causing problems with vision, balance, muscle control and other...   Read More

Panel releases best practices in cost-effectiveness analysis

By Lauren Neves  |    October 3, 2016
Recently, the Journal of the American Medical Association (JAMA) published findings and recommendations from the Second Panel on Cost-Effectiveness in Health and Medicine, detailing what the...   Read More

ICYMI: More than 60 PhRMA company scientists visit Capitol Hill

By Andrew Powaleny  |    September 30, 2016
Last week, PhRMA brought more than 60 member company researchers and scientists to Capitol Hill for a biopharmaceutical researcher fly-in. The fly-in highlighted the important science that’s...   Read More

ICYMI: Multi-stakeholder group recommended changes to support value-driven health care

By Michelle Drozd  |    September 14, 2016
As part of PhRMA’s efforts to explore policy solutions to promote value-driven health care, we recently participated in a forum convened by Deloitte and the Network for Excellence in Health...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates